The efficacy of pivmecillinam: 3 days or 5 days t.i.d against community acquired uncomplicated lower urinary tract infections – a randomized, double-blinded, placebo-controlled clinical trial study protocol

BMC Infectious Diseases

Study Protocol

Lars Bjerrum¹  Jenny Dahl Knudsen²  Filip Jansåker²  Niels Frimodt-Møller³ 

[1] Section of General Practice and Research Unit of General Practice, Department of Public Health, University of Copenhagen, Oester Farimagsgade 5, 1014, Copehangen K, Denmark;The Department of Clinical Microbiology, Copenhagen University Hospital, Hvidovre Hospital, Kettegård Allé 30, 2650, Hvidovre, Denmark;The Department of Clinical Microbiology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark;

关键词: Cystitis;    UTI;    Pivmecillinam;    General practice;    Study protocol;   

DOI  :  10.1186/s12879-016-2022-0

 received in 2016-09-06, accepted in 2016-11-14,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundUncomplicated lower urinary tract infections (LUTI) are very common, and presumably around 200,000 female patients are treated for this annually in Denmark. The current Danish national clinical practice guidelines recommend pivmecillinam as a first-line drug (i.e., 400 mg t.i.d. for 3 days). Pivmecillinam is also one of the first-line drugs recommended in the international guidelines for LUTIs (i.e., 400 mg b.i.d. for 5 days). The international recommended duration is based on evidence saying that a 7-day regimen is better than a 3-day regimen. However, no data says that a 5-day regimen is superior to a 3-day regimen. With this study we aim to identify and to compare the efficacy of pivmecillinam 400 mg t.i.d in a 3-day respectively 5-day regimen, against community acquired uncomplicated LUTI, i.e., in women at the age of 18–70 year old.Method/designThe general practitioner will at consultation give a suitable patient the opportunity to participate in the study. If the patient will give her consent, a double-blinded kit (i.e., the antibiotic with/without placebo, questionnaires and self-urinary samples) will be given to the patient. We aim for 161 evaluable patients in each arm.DiscussionPivmecillinam is an excellent choice against urinary tract infections and we believe this study will fill in the gaps and strengthen the evidence on the treatment against one of the most common infections in our society. Thus, aiming to provide a more rational and ecological beneficial antimicrobial therapy.Trial registrationEudraCTno.: 2014-001321-32.

【 授权许可】

CC BY   
© The Author(s). 2016